This is a Phase 1/2, open-label, multi-center study to assess the efficacy, safety,
tolerability, pharmacokinetics, including recommended phase 2 dose (RP2D) of HM43239
monotherapy in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML).
Phase 1/Phase 2
Aptose Biosciences Inc.
The following cities have HM43239 clinical trial sites. Please check back often as locations will be updated.
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.